AstraZeneca says Imjudo-Imfinzi combination approved for advanced liver cancer in US
The HIMALAYA Phase III trial showed that a single priming dose of Imjudo added to Imfinzi reduced the risk of death by 22% compared with sorafenib
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1094 stories · page 4 of 11
AstraZeneca earnings to fall due to lower sales and higher costs
AstraZeneca core average earnings per share will fall 5.5% predicts Credit Suisse
AstraZeneca set for strong third-quarter; brokers think the stock is worth £125
Shore Capital is one of 21 banks and brokers following AZ that are bullish on the outlook for the Anglo-Swedish drugs giant and its share price
AstraZeneca sees COVID-19 vaccine suffer a setback in nasal spray trial
An antibody response in the respiratory mucous membranes was seen in only a minority of participants in the trial, which was in the first of usually three phases of clinical testing, the University of Oxford said in a statement
AstraZeneca gets its third regulatory green light in a matter of weeks for asthma drug
The treatment has been approved in Japan for severe bronchial asthma where high-dose traditional corticosteroids don’t work
AstraZeneca wins European approval for Ultomiris autoimmune disease treatment
The nod from the European Commission paves the way for the first long-acting C5 inhibitor for generalised myasthenia gravis
AstraZeneca receives China green light for Lynparza
The drug will be used as a maintenance treatment in women with an advanced form of ovarian cancer
AstraZeneca says Evusheld approved for treatment of COVID-19 in EU
Evusheld has been shown to significantly reduce the risk of severe COVID-19 or death
AstraZeneca gets EU backing for COVID-19 treatment and RSV drug
If Beyfortus receives marketing approval, it would be the first single-dose preventative therapy for RSV for infants
Archive
Market movers: Property groups fall as Goldman/JPMorgan reduce price targets
A look at some risers and fallers in the market today.
Archive
FTSE 100 closes in the red as the investor gloom continues
Britain's blue-chip index finished around 45 points lower, or 0.62%, at 7,236 on the day
AstraZeneca wins injunction preventing former executive from joining GSK
AstraZeneca secured a victory in its battle with GSK in its executive tug of war at the last moment - at least for now
AstraZeneca's Farxiga successfully used to treat heart failure
The new indication could increase Farxiga's addressable market by 50%
AstraZeneca looking for bolt-on acquisitions
Pascal Soriot said the FTSE 100 giant is particularly interested in firms that specialise in oncology and cardiovascular treatments
AstraZeneca breast cancer drug performs well in latest trial
The results of the confirmatory assessment mirrored earlier positive data
AstraZeneca chemotherapy signed off for use in people with lung cancer
The US Food & Drug Administration has provided its seal of approval for Enhertu
AstraZeneca breast cancer drug gets the green light
The Anglo-Swedish drugs giant has hailed Enhertu as as potentially transformational treatment
AstraZeneca follows the trend in the sector to upgrade guidance as Covid vaccines sales show resilience
Instead of dropping by up to a quarter, sales of Vaxzevria will now be flat
Archive
FTSE 100 closes higher on final session of July as Wall Street extends post-earnings run
At the close, the UK blue-chip index was up 78.18 points, or 1.1% at 7,423.23, just below the morning peak of 7,441.20 and well above the opening low of 7,345.25
AstraZeneca delivers a triple dose of drug updates
It has received two drug approvals and a priority review
AstraZeneca acquires blood cancer specialist TeneoTwo for up to US$1.2bn
By redirecting the body's natural immune response to target B-cell malignancies, the TNB-486 drug being developed by TeneoTwo could be used alone or in combination, adding a new weapon to AstraZeneca's haematology portfolio
AstraZeneca hails phase III success of drug for rare disease amyloid polyneuropathy
It will file a new drug application later this year
AstraZeneca downgraded by UBS on lack of catalysts until 2023
In the longer term, the pharma analysts believe that the drug company “has the potential to build out a platform of antibody-drug conjugates” of which Enhertu is the first
Archive
FIVE at FIVE: De Pfeffel kerfuffle; Musk in handbrake turn; Countryside Partnerships under siege; AstraZeneca finds market hard to please
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news.
AstraZeneca wows peers but misses out on post-Jubilee bounce
Analysts expected a rally in the pharma group's shares following its critical update on breast cancer drug Enhertu at the ASCO conference this weekend
AstraZeneca beats profit and revenue forecasts; to open new R&D site
The pharma group still expects full-year revenue percentage growth in the high teens
AstraZeneca says liver cancer treatment combo accepted for US priority review
According to a phase III trial, patients treated with a combination of tremelimumab and Imfinzi experienced a 22% reduction in the risk of death
AstraZeneca a 'buy' for Deutsche Bank after lung cancer drug granted priority review
Deutsche Bank gave the drug-maker a price target of 11,500p, approximately 10% higher than Tuesday’s closing price
AstraZeneca cancer drug receives priority FDA review as data points to its potential in lung cancer
AstraZeneca said it believes Enhertu could become the standard of care for a certain group of lung cancer sufferers for whom there is no targeted treatment
Are AstraZeneca PLC shares a 'buy'? This leading bank is a fan
Deutsche Bank has raised its price target on stock in the Anglo-Swedish group
AstraZeneca's Ondexxya wins approval for reversal of acute major bleeds in patients
Ondexxya was also approved in Japan for use along with all three FXa inhibitors: apixaban, rivaroxaban, or edoxaban
AstraZeneca's COVID drug bags EU approval
Evusheld may be particularly beneficial for people not adequately protected by a COVID-19 vaccine
AstraZeneca's Imfinzi fails to meet primary endpoint in phase 3 cervical cancer trial
“While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development programme, exploring the benefits of Imfinzi in many tumour types,”
AstraZeneca ready to drop US approval attempt for Covid vaccine - report
Shares in AstraZeneca are at their highest level ever
AstraZeneca’s COVID vaccine alternative gets UK green light
While vaccines are seen as the first-line defence against COVID-19, the medical regulator said this drug was for those who "may not respond adequately to these vaccines and for a small number of individuals COVID-19 vaccines may not be reco
AstraZeneca to pay US$775mln to settle Alexion patent dispute
The litigation with the Chugai Pharmaceutical Company relates to a drug called Ultomiris
AstraZeneca's COVID-19 drug application under review by EU regulators
The EU drug regulator began reviewing the data on AstraZeneca's antibody cocktail last October
Nine FTSE companies to hedge the risk of Russia's invasion of Ukraine
“Hedging macro risk is likely to remain important for equity investors in the near term,” the analysts said
AstraZeneca and Neurimmune land US$760mln deal for heart disease drug
Deal will see AstraZeneca's subsidiary develop, manufacture and commercialise NI006, with initial payment to Neurimmune of US$30mln
AstraZeneca’s Enhertu shown to improve survival in breast cancer patients in pivotal trial
The trial results offer the potential to redefine how the disease is classified and treated, the drug giant said
AstraZeneca EU wins approval for the first drug in more than a decade for lupus
AZ's Saphnelo works by dampening the excessive type I interferon signature that is found in many patients
AstraZeneca drug could help prolong life of terminally ill prostate cancer patients
AZ's Lynparza in combination with a common hormone therapy delayed disease progression versus the current standard of care by more than eight months
AstraZeneca boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet
Revenues grew 41% with core EPS up 32%; the Anglo-Swedish giant remains bullish on the outlook
AstraZeneca looks beyond Covid, US inflation and Unilever under pressure: Thursday's agenda
Another set of big names reports tomorrow while price rises in the US will set the afternoon tone
Will Pfizer's success push AstraZeneca and GlaxoSmithKline investors over the edge?
Pfizer expects to receive a continued boost from its Covid jab. Investors in AZ and GSK will likely look on in envy
AstraZeneca Covid jab criticism cost 'hundreds of thousands' of lives claims professor
“Bad behaviour from scientists and from politicians has probably killed hundreds of thousands of people"
AstraZeneca PLC cancer drug offers hope to sufferers of a rare but aggressive form of the disease
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
AstraZeneca PLC cancer drug offers hope to sufferers of a rare but aggressive form of the disease
The company's treatment Imfinzi when used with chemotherapy reduced the risk of death by 20% in patients with advanced biliary tract cancer
Investments and investor services
AstraZeneca's Enhertu granted Priority Review for breast cancer in US
In a trial, Enhertu reduced the risk of disease progression or death by 72% versus a prior treatment
AstraZeneca and Neurimmune sign deal to develop and commercialise treatment for fatal condition ATTR-CM
Neurimmune will receive an upfront payment of US$30mln from Alexion with potential milestone payments of up to US$730mln
AstraZeneca says COVID-19 booster effective against Omicron variant
A third dose of the AstraZeneca/Oxford Uni vaccine produced higher levels of neutralising antibodies than those found in persons who had recovered naturally from the alpha, beta and delta variants
AstraZeneca’s lupus treatment Saphnelo recommended for approval in the EU
If approved, Saphnelo would be the first new treatment for systemic lupus erythematosus (SLE) in Europe in more than a decade
AstraZeneca and Amgen’s Tezspire approved in US for severe asthma
Tezspire is the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients, the pharma giant said
Citi recommends buy of AstraZeneca on the back of Evusheld announcement
Citi recommends Buy of AstraZeneca stock on the back of Evusheld announcement.
Oxford University paper supports the view that a booster jab is advisable to ward off the Omicron variant of Covid-19
If the scientists are to be believed, it looks like being double-jabbed offers less protection against the Omicron variant than the Delta one
AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions
The blockbuster acquisition by AstraZeneca distorted the figures somewhat, with the number of M&A deals declining in the quarter
AstraZeneca agrees licensing deal with California biotech worth up to US$3.5bn
The Anglo-Swedish giant is teaming up with Ionis Pharmaceuticals, which is developing a breakthrough drug for a fatal heart condition
Oxford University says it can quickly update AstraZeneca’s COVID-19 vaccine
It noted that there is no evidence so far that existing vaccines will not provide protection against the Omicron variant
Archive
FTSE 100 falls flat at the close on Omicron concerns
The UK blue chip index sank even further while US market fall not as bad as feared
New Covid-19 super-variant "the worst seen so far"
The key question is how governments will respond in the event that the ‘nu’ (B.1.1.529) strain spreads.
AstraZeneca boss suggests Europe's Covid-19 spike linked to vaccine snub
"In the UK the vaccine was used to vaccinate older people whereas in Europe people thought initially the vaccine doesn’t work in older people"
AstraZeneca preventative COVID-19 jab shown to cut risk of severe disease and death by over 80%
Six months of protection was maintained despite the surge of the Delta variant
AstraZeneca: Making sense of the Q3 numbers
Both Deutsche Bank and UBS have put out (very short) updates post-results
AstraZeneca targets a 'modest' profit from COVID-19 vaccine
The company is moving away from the not-for-profit pledge made during the pandemic
Builders and building materials
AstraZeneca facing raised expectations
Trading updates are expected from AstraZeneca, while housebuilders Galliford Try and Redrow have annual general meetings.
AstraZeneca in demand as analysts see further upside
Barclays sees AstraZeneca as the top pick in the sector.
AstraZeneca's premium growth story still not appreciated by the market, leading investment bank says
Swiss group UBS Tuesday restated its 'buy' advice and £100 a share price target
AstraZeneca posts stellar late-stage trial results for advanced biliary tract cancer candidate
The candidate demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to standard of care
AstraZeneca 'top pick' in pharma sector as JP Morgan predicts big growth ahead
JPM sees Astra achieving core earnings growth of 33%, 27% and 23% in the next three years
Valneva says COVID-19 vaccine better than AstraZeneca in clinical trials
The candidate was found to lead to a stronger immune response and to cause fewer side effects compared to its competitor
AstraZeneca says phase III trial shows Imfinzi and tremelimumab combination improves liver cancer survival rate
"This is the first time a dual immunotherapy regimen has improved overall survival as a 1st-line treatment for patients with unresectable liver cancer for whom treatment options are limited and long-term outcomes are poor," said Susan Galbr
Will COVID-19 treatment keep a lid on winter infections?
Merck and AstraZeneca have developed medicines that can prevent people infected with the virus from developing serious symptoms
AstraZeneca's investment in research and development is paying off but market is yet to fully recognise its potential, says investment bank
The median price target for AZ shares is £99.91, suggesting upside of 11.5% from current levels. Investment bank Berenberg reckons the stock is worth £105
AstraZeneca antibody treatment halves COVID-19 deaths in new trial
AZD7442 is the first LAAB with Phase III data to demonstrate benefit in both prophylaxis and treatment of COVID-19, said the pharma giant
AstraZeneca seeks emergency use authorisation for COVID-19 antibody drug in US
Phase III trial results showed showed a 77% reduction in risk of developing symptomatic COVID-19 with the long-acting antibody combination AZD7442
AstraZeneca to buy rare disease group Caelum Biosciences for up to US$500m
Caleum is investigating a drug to treat light chain amyloidosis, a fatal, rare disease in which abnormal proteins build up in organs throughout the body
AstraZeneca: Where now for the shares and the vaccines business? And why no good deed goes unpunished
While chief executive Pascal Soriot has said he had no regrets over getting involved in vaccines, there is a growing recognition among execs that a rethink may be in order
Is AstraZeneca ready to leave COVID-19 vaccines behind?
The pharma giant has racked in successes in its oncology pipeline and it's also entering the rare disease world with Alexion: is it time to move on?
AstraZeneca posts positive results for prostate cancer candidate
Lynparza used with the current standard of care showed better results than the standard of care alone
Oxford Biomedica revenues jump 139% as COVID-19 vaccine manufacturer builds stake
Revenue was lifted by the COVID-19 vaccine agreement with AstraZeneca
AstraZeneca to invest US$360mln in manufacturing plant in Ireland
The new facility is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs
AstraZeneca: £2bn added to the value after "ground-breaking" breast cancer trial results. But just how much higher will its shares go?
Two leading banks reckon the the stock could kick on after Monday's move higher
COVID-19 booster jab not needed for 'everybody', AstraZeneca vaccine creator says
"Immunity is lasting well in the majority of people," Prof Dame Sarah Gilbert told the Telegraph
Covid booster jabs given all clear by UK medicine regulator
"It will now be for the (JCVI) to advise on whether booster jabs will be given."
AstraZeneca asthma candidate passes clinical trials with flying colours
The drug met all primary goals in two late-stage studies involving over 4,000 people
AstraZeneca boss says booster jab might be unnecessary
“A third dose for all may be needed, but it may not"
AstraZeneca and EU settle dispute over COVID-19 vaccine delivery
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
AstraZeneca and EU settle dispute over Covid-19 vaccine delivery
Under the settlement announced by the European Commission, AstraZeneca will deliver 200 million doses by the end of March 2022
AstraZeneca/Oxford vaccine to be trialed as cancer treatment
The anti-cancer vaccine was designed to target two MAGE-type proteins found on many cancer cells
University study of COVID-19 vaccines rebuts fears of blood clots
The research team studied records of more than 29mln people who received the first dose of a COVID-19 vaccine between Dec and Apr, and the records of almost 1.8mln people who had been infected with the virus
AstraZeneca says ALXN1840 phase III trial in Wilson disease meets primary endpoint
ALXN1840, a potential new once-daily, oral medicine, demonstrated three times greater copper mobilisation than standard treatments
AstraZeneca’s Forxiga approved in Japan for chronic kidney disease
A phase III trial showed that Forxiga reduced the risk of worsening of renal function, onset of end-stage kidney disease or risk of cardiovascular or renal death by 39%
NHS preparing to vaccinate 12-15 year olds - reports
Reports have suggested the plan is to start vaccinations ahead of the September return to school.
AstraZeneca stops phase III trial for ALS drug
The trial of the group's Ultomiris treatment was halted due to lack of efficacy
AstraZeneca says antibody drug phase III trial shows significant reduction in symptomatic Covid-19
The company's AZD7442 drug reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo
Study shows vaccines work but fails to quell Delta variant concerns
“Both of these vaccines, at two doses, are still doing really well against Delta"
Are AstraZeneca shares worth buying? Read what this big hitting City broker has to say before making your call
“We see Astra’s sector discount unwinding, as the Alexion acquisition demonstrates continued strong top-line growth, coupled with significant operating margin expansion and increased free cash flow generation,” JP Morgan Cazenove said in it
AstraZeneca offers sector-leading growth at reasonable price, says Morgan Stanley
The investment bank resumed coverage with an ‘overweight’ recommendation and a 9,800p target price
AstraZeneca receives EU approval for chronic kidney disease drug
The group also announced positive final-stage trial results for Enhertu on breast cancer patients
Government wants UK investment 'big bang' to compete with US giants
It’s time we recognised the quality that other countries see in the UK, and back ourselves by investing more money"